Rating Change
Piper Sandler analysts initiated coverage on Jasper Therapeutics, Inc. (NASDAQ:JSPR) with a rating of Overweight on August 12, 2026.
new coverageNASDAQ:JSPR
Piper Sandler Initiates Coverage on Jasper Therapeutics, Inc. (JSPR) with Overweight
Piper Sandler analysts initiated coverage on Jasper Therapeutics, Inc. (NASDAQ:JSPR) with a rating of Overweight on August 12, 2026.
At publication ·
What changed
Jasper Therapeutics, Inc. (NASDAQ:JSPR) · new coverage
- Firm
- Piper Sandler
- Rating
- Overweight
- Price at event
- $0.82
- Market capitalization
- $29.9M
At a glance
Key takeaways
- Piper Sandler initiated coverage of Jasper Therapeutics (JSPR) with an Overweight rating on August 12, 2026.
- The stock trades at $0.82 with a market capitalization of $29.9 million and has declined 68.7% over the past 52 weeks.
Market Context
Jasper Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $0.82 with a market capitalization of $29.9M. The stock has declined 68.7% over the past 52 weeks.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Jasper Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Jasper Therapeutics, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Overweight | N/A |
| May 15, 2026 | TD Cowen | Hold | N/A |
| May 15, 2026 | RBC Capital | Sector Perform | N/A |
| Apr 01, 2026 | Evercore ISI Group | Outperform | N/A |
| Nov 11, 2025 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View JSPR Stock Page
Frequently Asked Questions
What does the Overweight rating mean for JSPR?
A rating of Overweight from Piper Sandler reflects the analyst's outlook on Jasper Therapeutics, Inc. (NASDAQ:JSPR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the JSPR forecast page.